Aspiring clinicians earn white coats during annual ceremonies

Weill Cornell Medicine celebrated the incoming physician assistant students in the Class of 2028 and first-year medical students in the Class of 2030 Aug. 18 during two White Coat Ceremonies.

Research helps NYC students aim higher in public high school applications

Many New York City eighth-graders – particularly those from underserved communities – aren’t applying to academically competitive high schools where they could succeed, according to new Cornell research.

Cornell Tech’s new faculty are changing how AI learns, reasons, solves problems

Six new faculty members will join Cornell Tech during the coming year, bringing expertise in AI, machine learning, programming languages, and operations research.

Around Cornell

Traumatic brain injury in Pakistan linked to poor long-term survival

Traumatic brain injury in Pakistan is associated with a high risk of death and disability long after the initial injury, even in mild to moderate cases.

Ari Juels receives USENIX Security Test of Time Award

A decade later, his paper is widely recognized as foundational to the field of AI security.

Around Cornell

Protein secreted by immune cells may help drive brain aging

Brain-resident immune cells that have reached an old-age state called “senescence” secrete a protein that causes dysfunction in other brain cells, according to Weill Cornell Medicine researchers, a finding that could shed light on memory loss.

Riders love e-buses but drivers prefer their cars, study finds

Researchers found that while the smoother, quieter ride of an electric bus was appealing to those who already rode public transportation, those advantages weren’t enough to lure drivers away from their cars.

Molecular structures provide roadmap for targeted Parkinson’s disease therapeutics

Researchers have uncovered how a key Parkinson’s protein shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein into an overactive state. 

Breakthrough may change treatment for metastatic prostate cancer

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial.